All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Steven Treon from Dana-Farber Cancer Institute, Boston, US, about the long-term outcomes of patients with Waldenstrom's macroglobulinemia treated with ibrutinib.
Steven Treon discusses the long-term follow-up of a multi-institutional trial investigating ibrutinib, which is highly active in patients with Waldenstrom's macroglobulinemia.
Long-term outcomes of patients with Waldenstrom's macroglobulinemia treated with ibrutinib
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Educational theme: Advances in treating Waldenström's macroglobulinemia
Over the next month, the Lymphoma Hub will be focusing on a new educational theme: Advances in treating Waldenström's macroglobulinemia. This article introduces the topic and...
Lymphoma Hub Satellite Symposium 2019 | Chemo-free approaches in MCL - Professor Simon Rule
Professor Simon Rule discussed the novel chemotherapy-free treatment approaches in MCL during the Lymphoma Hub Satellite Symposium at 15-ICML.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox